Astellas And Maxygen Ink Global Development Deal For Autoimmune Candidate MAXY-4
This article was originally published in PharmAsia News
Executive Summary
Maxygen's early-July decision to bear down on advancing its lead neutropenia compound and next-generation CTLA4-Ig drugs, letting Bayer take its hemophilia program, is paying off with Astellas, which signed a global deal that brings $10 million up front
You may also be interested in...
Astellas Submits Pediatric Data To U.S. FDA For Flomax Exclusivity; Announces JV With Maxygen
TOKYO - Astellas Pharma July 1 said its U.S. licensee for Flomax (tamsulosin), Boehringer Ingelheim Pharmaceuticals submitted data to U.S. FDA from a study on pediatric patients with neurogenic bladders - apparently to fend off generics offerings when the drug's patent protection expires later this year
Astellas Submits Pediatric Data To U.S. FDA For Flomax Exclusivity; Announces JV With Maxygen
TOKYO - Astellas Pharma July 1 said its U.S. licensee for Flomax (tamsulosin), Boehringer Ingelheim Pharmaceuticals submitted data to U.S. FDA from a study on pediatric patients with neurogenic bladders - apparently to fend off generics offerings when the drug's patent protection expires later this year
Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move
TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill